Eli Lilly Initiates First Clinical Trial of FRα-Targeting ADC LY4170156

On May 6, according to ClinicalTrials.gov, Eli Lilly and CompanyLY4170156 Initiated Clinical Trials for the First Time, This is aFRα ADC。

Source: ClinicalTrials.gov Official Website

According to the Insight database,Currently, there are only 9 products globallyFRα ADC Enters Clinical Stage。Among them,SomiromabIt is the only approved product on the market, having received accelerated approval from the U.S. FDA in November 2022 for the treatment of adult patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have previously undergone 1-3 lines of systemic therapy.

Earlier in October 2020,ImmunoGen has licensed the rights of mirvetuximab soravtansine in Greater China toHuadong Medicine, obtain$40 millionAn upfront payment and potential milestone payments of up to $265 million.Somiromab was submitted for marketing approval in China last October and is currently under review.

And in August of last year,ImmunoGen &Takeda达成合作。The latter will receiveSomiromabDevelopment and commercialization rights in Japan. The formerwill receive payment from Takeda$34 Million Upfront PaymentAnd recent milestone payments,And is eligible to receive potential regulatory and commercial milestone payments, as well as double-digit sales royalties.Thereafter,ImmunoGen Acquired by AbbVie for $10.1 billion.

In China, there are only 6 kinds ofFRα ADC In the clinical stage, the enterprises involved in the layoutHuadong Medicine、AstraZeneca, Provention Bio, Prolific Discovery, Bio-Thera Solutions, and Tasly. ExceptOutside of Somytomab, the rest are still in relatively early stages. Notably, last month, Provention Bio...$1.8 billion wasGenmab's acquisition, it's not hard to see the latter's impact on the formerApproval of the new FRα ADC drug Rina-S.

【Recommended Reading】

$1.8 Billion! Genmab Acquires Provention Bio